Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald B Vender

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Dermatology and Therapy|December 23, 2021
Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based MethodologyKim A Papp, Melinda J Gooderham, Charles W Lynde, et al.
Dermatology and Therapy|April 21, 2022
Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Jennifer Beecker, Curtis Cooper, et al.
Dermatology and Therapy|March 17, 2023
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Barbara Melosky, Sandeep Sehdev, et al.
Dermatology and Therapy|July 6, 2023
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Barbara Melosky, Sandeep Sehdev, et al.
Dermatology and Therapy|July 6, 2023
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Jennifer Beecker, Curtis Cooper, et al.
The British Journal of Dermatology|July 3, 2026
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 TrialsLinda Stein Gold, April W Armstrong, Jennifer Soung, et al.
The Journal of Rheumatology|June 13, 2017
Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily PracticeDafna D Gladman, Yves Poulin, Karen Adams, et al.
Dermatology and Therapy|January 23, 2026
Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective StudyTiago Torres, Siddhartha Sood, Orhan Yilmaz, et al.
Clinical and Experimental Dermatology|July 29, 2025
Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicenter retrospective studyTiago Torres, Siddhartha Sood, Orhan Yilmaz, et al.
Lancet (London, England)|September 21, 2025
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trialsLinda Stein Gold, April W Armstrong, Robert Bissonnette, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Dermatology and Therapy|December 23, 2021
Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based MethodologyKim A Papp, Melinda J Gooderham, Charles W Lynde, et al.
Dermatology and Therapy|April 21, 2022
Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Jennifer Beecker, Curtis Cooper, et al.
Dermatology and Therapy|March 17, 2023
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Barbara Melosky, Sandeep Sehdev, et al.
Dermatology and Therapy|July 6, 2023
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Barbara Melosky, Sandeep Sehdev, et al.
Dermatology and Therapy|July 6, 2023
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Jennifer Beecker, Curtis Cooper, et al.
The British Journal of Dermatology|July 3, 2026
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 TrialsLinda Stein Gold, April W Armstrong, Jennifer Soung, et al.
The Journal of Rheumatology|June 13, 2017
Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily PracticeDafna D Gladman, Yves Poulin, Karen Adams, et al.
Dermatology and Therapy|January 23, 2026
Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective StudyTiago Torres, Siddhartha Sood, Orhan Yilmaz, et al.
Clinical and Experimental Dermatology|July 29, 2025
Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicenter retrospective studyTiago Torres, Siddhartha Sood, Orhan Yilmaz, et al.
Lancet (London, England)|September 21, 2025
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trialsLinda Stein Gold, April W Armstrong, Robert Bissonnette, et al.
Pageof 3